Ursodiol Articles
Japan stock market week to Jan 21, 2008
28 January 2008
Axcan agrees to $1.3B private equity buy-out
10 December 2007
480B yen sales target for Mitsubishi Tanabe
28 May 2007
Axcan launches new URSO formulation
31 March 2003
Axcan outperforms in 1st qtr on acquisitions
17 February 2003
Axcan licenses Aventis' Delursan for $22.8M
27 January 2003
Axcan's URSO 250 has efficacy, says firm
12 August 2002
Watson gets Actigall rights from Novartis
11 February 2002
Axcan reimburses loan to Schwarz Pharma
2 July 2001
Analysts expectant on future prospects for Canada's Axcan Pharma
13 February 2001
Axcan drug" promising" in colorectal polyps
27 November 2000
Novartis files petition against URSO
22 July 1999
Ursodiol Cleared In USA For Liver Disease
18 December 1997
Novartis Launches Actigall In USA
12 May 1997
Axcan Gets Approvable Letter For Urso
7 April 1997
Axcan Pharma Starts Ph III With Urso
27 January 1997
FDA Accepts Axcan NDA For Ursodiol As PBC Therapy
16 September 1996
Ciba Reveals Pipeline With Broad Reach
17 April 1995
SALES AND PROFITS UP AT TOKYO TANABE
1 June 1992
Showing 1-22 of 22 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
